3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
681
Neoplasms
593
Carcinoma, Non-Small-Cell Lung
292
Colorectal Neoplasms
291
Prostatic Neoplasms
284
Lung Neoplasms
224
Melanoma
161
Multiple Myeloma
151
Neoplasm Metastasis
145
Pancreatic Neoplasms
143
Head and Neck Neoplasms
143
Ovarian Neoplasms
136
Carcinoma, Hepatocellular
126
Leukemia, Myeloid, Acute
122
Colonic Neoplasms
114
Brain Neoplasms
113
Squamous Cell Carcinoma of Head and Neck
111
Uterine Cervical Neoplasms
109
Stomach Neoplasms
104
Lymphoma
101
Recurrence
100
Glioblastoma
96
Precursor Cell Lymphoblastic Leukemia-Lymphoma
83
Lymphoma, Non-Hodgkin
82
Urinary Bladder Neoplasms
78
Lymphoma, Follicular
78
Hematologic Neoplasms
78
Glioma
75
Parkinson Disease 4, Autosomal Dominant Lewy Body
73
Sarcoma
72
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
1 year
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA